CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 131 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2017. The put-call ratio across all filers is 1.26 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $256,000 | -35.5% | 103,800 | -5.7% | 0.22% | -40.8% |
| Q1 2017 | $397,000 | +2.1% | 110,050 | +0.1% | 0.37% | -11.7% |
| Q4 2016 | $389,000 | -14.1% | 109,950 | -2.0% | 0.42% | -3.7% |
| Q3 2016 | $453,000 | -7.6% | 112,200 | +0.5% | 0.44% | -15.7% |
| Q2 2016 | $490,000 | +84.2% | 111,600 | +58.5% | 0.52% | +76.1% |
| Q1 2016 | $266,000 | -65.0% | 70,400 | +45.3% | 0.29% | -63.7% |
| Q4 2015 | $760,000 | – | 48,450 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,006 | $19,497,000 | 100.00% |
| Meditor Group Ltd | 6,312,700 | $17,928,000 | 2.31% |
| TSP Capital Management Group, LLC | 1,278,057 | $3,630,000 | 1.65% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 10,772,111 | $30,593,000 | 0.46% |
| Virtus ETF Advisers LLC | 118,969 | $338,000 | 0.42% |
| Benchmark Capital Advisors | 61,000 | $173,000 | 0.14% |
| ASCEND CAPITAL, LLC | 873,995 | $2,482,000 | 0.09% |
| SHEPHERD KAPLAN KROCHUK, LLC | 44,521 | $126,000 | 0.08% |
| Vident Investment Advisory, LLC | 427,578 | $1,214,000 | 0.06% |
| NJ State Employees Deferred Compensation Plan | 80,000 | $227,000 | 0.04% |